Healthcare >> Sector Roundtables >> February 14, 2005
DAVID MOSKOWITZ is Managing Director of the healthcare research group at
Friedman, Billings, Ramsey Group, Inc. He joined FBR in July 2001 and
currently covers the large cap pharmaceutical sector in addition to
select specialty pharmaceutical companies. From 1999 to 2001, Mr.
Moskowitz worked for UBS Warburg as a specialty pharmaceuticals analyst,
and from 1998 to 1999, he was a biotechnology analyst for Standard &
Poor's. Prior to entering the financial services industry, Mr. Moskowitz
practiced as a Registered Pharmacist in various hospital and retail
settings for nearly 10 years. Mr. Moskowitz received his BS degree in
Pharmacy from Rutgers University and his MBA degree in Finance and
Pharmaceutical Industry Studies from Fairleigh Dickinson University. Profile
AL RAUCH, Vice President at A.G. Edwards & Sons, Inc., and Chartered
Financial Analyst, has been covering the healthcare industry for over 10
years. Prior to joining A.G. Edwards, he was Managing Director and Head
of Health Care Equity Research at Ladenburg Thalmann. Previously he was
at Wachovia (formerly First Union) and was part of its acquisition of
EVEREN Securities. Prior to this he was at A.G. Edwards in St. Louis for
one and one-half years. Mr. Rauch comes from the pharmaceutical industry
and was in drug discovery at Pfizer for six years. He was a faculty
member at Wake Forest Medical School for three years and did a two-year
postdoctoral fellowship in the Department of Physiology and Pharmacology
at Wake Forest. He has a PhD in Pathology from Emory University in
Atlanta and an MBA from RPI in New York. Profile
hot button at this point? What's the key issue from your perspective?
Mr. Moskowitz: I think the key issue for large
